Home›Research›Compare›Oxyntomodulin vs Semaglutide
Peptide ComparisonOxyntomodulin vs Semaglutide
Both are Metabolic peptides.
Oxyntomodulin
OXM
No providers listed yet
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
806 providers listed
Semaglutide is FDA-approved, while Oxyntomodulin is investigational — the clearest structural difference between them.
Oxyntomodulin
Half-life
—
Semaglutide
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Semaglutide |
| Further along in FDA review | Semaglutide |
| Oral administration option | Semaglutide |
| More provider options (0 vs 806) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Oxyntomodulin
Semaglutide
Oxyntomodulin
Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…
Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity a…
Regulators of Appetite in Mammals - Old and New players.
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
About Oxyntomodulin
Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Oxyntomodulin
Class-based (investigational)
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Oxyntomodulin
Not enough vendor pricing yet.
Semaglutide
Where to source these peptides
Oxyntomodulin
Browse directory →
Providers offeringSemaglutide
806 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Oxyntomodulin vs Semaglutide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/oxyntomodulin/semaglutide